SG11202110659SA - Method for treating ocular diseases - Google Patents

Method for treating ocular diseases

Info

Publication number
SG11202110659SA
SG11202110659SA SG11202110659SA SG11202110659SA SG11202110659SA SG 11202110659S A SG11202110659S A SG 11202110659SA SG 11202110659S A SG11202110659S A SG 11202110659SA SG 11202110659S A SG11202110659S A SG 11202110659SA SG 11202110659S A SG11202110659S A SG 11202110659SA
Authority
SG
Singapore
Prior art keywords
hhh
hhh hhh
ohhh
diabetic retinopathy
age
Prior art date
Application number
SG11202110659SA
Other languages
English (en)
Inventor
Shoei-Sheng Lee
Ming-Jai Su
Lung-Jr Lin
Chao-Min Hsu
Original Assignee
Zih Yuan Tang Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zih Yuan Tang Biotechnology Co Ltd filed Critical Zih Yuan Tang Biotechnology Co Ltd
Publication of SG11202110659SA publication Critical patent/SG11202110659SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202110659SA 2019-04-03 2020-04-01 Method for treating ocular diseases SG11202110659SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828616P 2019-04-03 2019-04-03
US201962899279P 2019-09-12 2019-09-12
PCT/CN2020/082765 WO2020200241A1 (en) 2019-04-03 2020-04-01 Method for treating ocular diseases

Publications (1)

Publication Number Publication Date
SG11202110659SA true SG11202110659SA (en) 2021-10-28

Family

ID=72662774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110659SA SG11202110659SA (en) 2019-04-03 2020-04-01 Method for treating ocular diseases

Country Status (8)

Country Link
US (1) US11033603B2 (https=)
EP (1) EP3946414B1 (https=)
JP (1) JP7461663B2 (https=)
KR (1) KR20210149087A (https=)
CN (1) CN113795268B (https=)
SG (1) SG11202110659SA (https=)
TW (1) TWI818168B (https=)
WO (1) WO2020200241A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788083B (zh) * 2021-11-03 2022-12-21 葡萄王生技股份有限公司 蟬花菌絲體活性物質用於治療黃斑部病變之用途
CN120936366A (zh) * 2023-03-20 2025-11-11 资元堂生物科技股份有限公司 一种白殭菌素用于制备抑制血管新生药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0327316A (ja) * 1989-06-23 1991-02-05 Kitasato Inst:The 高脂血症治療剤
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
CN101669939A (zh) * 2009-09-22 2010-03-17 中山大学 恩镰孢菌素类化合物在制备抗耐药结核菌药物中的应用
US20140275091A1 (en) * 2013-03-15 2014-09-18 Coyote Pharmaceuticals, Inc. Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
US20140371158A1 (en) * 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway
CN109200066A (zh) * 2017-07-07 2019-01-15 葡萄王生技股份有限公司 蝉花活性物质及其用于预防、延缓或治疗白内障的用途

Also Published As

Publication number Publication date
EP3946414A4 (en) 2022-12-07
US20200316165A1 (en) 2020-10-08
JP7461663B2 (ja) 2024-04-04
KR20210149087A (ko) 2021-12-08
JP2022528566A (ja) 2022-06-14
CN113795268B (zh) 2025-04-08
WO2020200241A1 (en) 2020-10-08
TW202102252A (zh) 2021-01-16
EP3946414A1 (en) 2022-02-09
EP3946414B1 (en) 2025-12-03
CA3132137A1 (en) 2020-10-08
EP3946414C0 (en) 2025-12-03
CN113795268A (zh) 2021-12-14
US11033603B2 (en) 2021-06-15
TWI818168B (zh) 2023-10-11

Similar Documents

Publication Publication Date Title
US10195161B2 (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
EP2755647B1 (en) Use of omega fatty acids for treating disease
US8097640B2 (en) Prophylactic or therapeutic agent for diabetic maculopathy
JP6820658B2 (ja) ジピリダモールを用いる眼疾患の治療において使用するための組成物
EP3946414B1 (en) Beauvericin for treating ocular diseases
CN1086132A (zh) 局部应用治疗眼内压升高的药物组合物
CA3132137C (en) Method for treating ocular diseases
Steigerwalt et al. Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E1 and steroids
JPH11349486A (ja) 糖尿病性網膜症治療のためのスロデキサイドを含有する医薬
CN116898800A (zh) 无防腐剂的眼科药物乳剂及其应用
DE19748417A1 (de) Verwendung von Thiaminen zur Prophylaxe und Therapie der diabetischen Retinopathie und Nephropathie
EP3331517B1 (fr) Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne
CN114732805A (zh) 厚朴酚的新用途
Cameron et al. DIABETIC RETINOPATHY AND CYANCOBALAMIN (VITAMIN B12): A PRELIMINARY REPORT
Garrigue et al. A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models
Gianni Belcaro et al. Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E
HK1168028A (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
HK1168028B (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones